Showing results (211-220 of 297) with videos related to

Sort By:
Pageof 30
Annals of the Rheumatic Diseases|December 11, 2021
Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritisSayam Dubash, Oras A Alabas, Xabier Michelena, et al.
Arthritis Care & Research|August 18, 2019
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II TrialPhilip S Helliwell, Atul Deodhar, Alice B Gottlieb, et al.
The Journal of Rheumatology|July 5, 2011
Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest groupLaura C Coates, Aizad Mumtaz, Philip S Helliwell, et al.
The Journal of Rheumatology|August 3, 2017
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic ArthritisWilliam Tillett, Emma Dures, Sarah Hewlett, et al.
The Journal of Rheumatology|November 3, 2014
Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic reviewMaria Laura Acosta Felquer, Laura C Coates, Enrique R Soriano, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Pustular Psoriasis and Associated Musculoskeletal DisordersKristina Callis Duffin, Hervé Bachelez, Philip J Mease, et al.
Rheumatology (Oxford, England)|April 21, 2011
Use of conservative and surgical foot care in an inception cohort of patients with rheumatoid arthritisMichael R Backhouse, Anne-Maree Keenan, Elizabeth M A Hensor, et al.
RMD Open|July 21, 2022
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trialPhilip S Helliwell, Phillip J Mease, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|December 14, 2002
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitisL C Doward, A Spoorenberg, S A Cook, et al.
ACR Open Rheumatology|February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 StudyChristopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
Pageof 30